期刊
CLINICAL & TRANSLATIONAL IMMUNOLOGY
卷 8, 期 5, 页码 -出版社
WILEY
DOI: 10.1002/cti2.1046
关键词
CAR; adoptive cell therapy; solid tumors; T cells
类别
资金
- National Health and Medical Research Council (NHMRC) [APP1062580, APP1132373]
- Cancer Council of Victoria [APP1143517]
- National Breast Cancer Foundation Fellowship [ECF-17-005]
- NHMRC Senior Research Fellowship [APP1136680]
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T-cell therapy in a subset of B-cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene-modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据